Author Page for Guoqiang Wang

The Tumor Immune Microenvironment Transcriptomic Subtypes of Colorectal Cancer for Prognosis and Development of Precise Immunotherapy

Number of pages: 30 Posted: 31 Jul 2019

Yunqiang Tang, Tufeng Chen, Yan Zhang, Xiaochen Zhao, Yuzi Zhang, Guoqiang Wang, Mengli Huang, Shangli Cai, Jing Zhao, Bo Wei and Jun Huang

Guangzhou Medical University - Affiliated Cancer Hospital & Institute, Sun Yat-sen University (SYSU) - Department of Gastrointestinal Surgery, Nanjing Medical University - Nanjing Medical Hospital, 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., Sun Yat-sen University (SYSU) - Department of Gastrointestinal Surgery and Sun Yat-sen University (SYSU) - Department of Colorectal Surgery

Downloads 160

Abstract:

2.

Immunotherapy Efficacy and Safety of Programmed Cell Death 1 (PD-1) versus Programmed Death Ligand-1 (PD-L1) Inhibitors in Pan-Cancer Patients: A Systematic Review and Meta-Analysis

Number of pages: 36 Posted: 12 May 2019

Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song, Chuang Qi, Qing Wang, Mengli Huang, Yuzi Zhang, Depei Huang, Yuezong Bai, Feng Sun, Shangli Cai, Zhijie Wang and Jie Wang

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, 3D Medicines, Inc., 3D Medicines, Inc., Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., Peking University - Department of Epidemiology and Biostatistics, 3D Medicines, Inc., Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology

Downloads 130

Citation 1

Abstract:

3.

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Outcomes of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors (ICIs)

Number of pages: 30 Posted: 03 Dec 2019

Ye Li, Zhibo Zhang, Yi Hu, Xiang Yan, Qi Song, Guoqiang Wang, Runzhe Chen, Jinliang Wang and Shunchang Jiao

Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Oncology, 3D Medicines, Inc., University of Texas at Houston - Department of Genomic Medicine, Government of the People's Republic of China - Department of Oncology and Government of the People's Republic of China - Department of Oncology

Downloads 50

Guoqiang Wang

3D Medicines, Inc.

3

340

1

Scholarly Papers (3)

The Tumor Immune Microenvironment Transcriptomic Subtypes of Colorectal Cancer for Prognosis and Development of Precise Immunotherapy

Abstract:

Immunotherapy Efficacy and Safety of Programmed Cell Death 1 (PD-1) versus Programmed Death Ligand-1 (PD-L1) Inhibitors in Pan-Cancer Patients: A Systematic Review and Meta-Analysis

Abstract:

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Outcomes of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors (ICIs)

Abstract: